Editors of Blood Select Top 10 Manuscripts from 2017
Studies Include Advancements in Treating Sickle Cell Disease and CAR T-Cell Therapies
(WASHINGTON, December 22, 2017) — This year, there have been more than 1,000 manuscripts published in Blood, the Journal of the American Society of Hematology. To recognize these achievements, Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD, have selected the top 10 most outstanding manuscripts of 2017.
“From major scientific advances and improving therapies in the developing world to harnessing cutting edge technology to conquer blood diseases, 2017 was a remarkable year for hematology,” said Dr. Löwenberg. “Hematology is the frontier for some of the most significant scientific achievements, and we’re honored to highlight some of the top contributions published this year in Blood, the top-cited journal of our field.”
To identify the following top manuscripts of the year, the editors considered quality of the work and interest to the field of hematology. The following articles are listed in no particular order.
- Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia; Opoka et al.
- Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM; Moreau et al.
- Ibrutinib for chronic graft-versus-host disease after failure of prior therapy; Miklos et al.
- Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura; Scully et al.
- Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide; Harrison, et al.
- Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study; Majeed et al.
- A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy; Kong et al.
- Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis; Kaufman et al.
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia; Stein, et al.
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults; Gardner et al.
The American Society of Hematology (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.
Contact:
Stephen Fitzmaurice
American Society of Hematology
[email protected]; 202-552-4927
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission